Background Intravenous (IV) drug delivery is commonly used for its rapid administration and immediate drug effect. Most studies compare IV to subcutaneous (SC) delivery in terms of safety and efficacy, but little is known about what patients prefer. Methods A systematic review was conducted by searching seven electronic databases for articles published up to February 2014. Included studies were randomized controlled trials (RCTs) and/or crossover designs investigating patient preference for SC versus IV administration. The risk of bias in the RCTs was determined using the Cochrane Collaboration tool. Reviewers independently extracted data and assessed the risk of bias. Any discrepancies were resolved by consensus. Results The search identified 115 publications, but few (6/115) met the inclusion criteria. Patient populations and drugs investigated were diverse. Four of six studies demonstrated a clear patient preference for SC administration. Main factors associated with SC preference were time saving and the ability to have treatment at home. Only three studies used study-specific instruments to measure preference. Conclusions Results suggest that patients prefer SC over IV delivery. Patient preference has clearly been neglected in clinical research, but it is important in medical decision making when choosing treatment methods as it has implications for adherence and quality of life. If the safety and efficacy of both administration routes are equivalent, then the most important factor should be patient preference as this will ensure optimal treatment adherence and ultimately improve patient experience or satisfaction. Future drug efficacy and safety studies should include contemporaneous, actual patient preference where possible, utilizing appropriate measures.
other aspects of social, occupational, and functional wellbeing. If drugs have similar efficacy, then patient preference for route of administration could be important and should support medical decision making. The various drug modalities, dosages, and frequencies offer a wide range of choices to suit patients' needs and preferences. Consideration of such factors may help address problems of treatment adherence, especially in chronic medical conditions. Improvements in modern treatments have turned some diseases into chronic conditions (such as diabetes and cancer), so determining individual acceptability and choice of type of drug administration could enhance adherence to therapeutic regimens.
The intravenous (IV) and subcutaneous (SC) routes of administration have both benefits and drawbacks. IV delivery is advantageous as it allows the effect of the drug to take place immediately, the rate of distribution can be controlled, it assists those patients who cannot tolerate a drug orally or who have swallowing difficulties, large doses can be infused expeditiously, and it permits continuous medication to be delivered [1] . Advantages of the SC route include the possibility of self-administration, greater mobility for patients, an alternative for patients with poor venous access, and administration at home, away from the hospital setting [2] . Cost is another element to take into account, and several studies have shown the cost effectiveness of SC delivery over the IV drug route [3] [4] [5] [6] . In addition, out-of-pocket costs for patients and their families having to take time off work and travel to hospital for IV treatment may be underestimated by clinicians and/or policy makers.
Many trials have compared IV and SC drug administration, with most reporting on drug efficacy and safety [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] . In the study by Moreau et al. [11] , patients with relapsed multiple myeloma (MM) were randomized to receive bortezomib by either SC administration or IV infusion. Results revealed that the efficacy of SC bortezomib was non-inferior to IV administration. Adverse events were reported in 57 % of patients in the SC group and in 70 % of the IV group, showing that SC had an improved safety profile. Because of these results, the SC route of bortezomib was authorized for use within Europe [17] . Although the drug was approved, and fewer adverse events might lead to reasonable assumptions that patients would prefer SC delivery, patient preference was not reported by the authors.
A recent two-stage study [16] demonstrated that the pharmacokinetic profile of SC rituximab in patients with previously untreated follicular lymphoma was non-inferior to IV rituximab and was not associated with new safety concerns. IV infusions lasted 1.5-6 h, whilst the median injection time for SC rituximab was 6 min, showing that SC delivery would improve convenience for the patient whilst decreasing the burden on healthcare costs. The authors state that they plan to investigate the views of healthcare professionals regarding their preferred administration route after completion of stage two of the study; however, it is unclear whether they also intend to address patient preference.
Drugs that are available in both IV and SC formulations enable patients receiving long-term treatment to be given the drug subcutaneously when, for example, repeated cannulation may have damaged peripheral veins. This was demonstrated in a study by Keystone et al. [14] . Patients with rheumatoid arthritis who received at least 4 years of IV abatacept continued via the SC method. Safety, efficacy, and immunogenicity was investigated, and results showed that switching from IV to SC administration was well tolerated, had no increased safety concerns or increased risk of immunogenicity, and efficacy was maintained. These features, paired with the fact that fewer than 10 % of patients discontinued SC treatment, suggest that patients may well prefer SC administration, although the study did not investigate this formally.
There are in fact few studies where patients' preferences or acceptance of IV and SC drug administration are primary outcomes [18] [19] [20] [21] [22] [23] [24] . One good example is the report by Barbee et al. [19] in which patients with MM who received at least one dose each of IV and SC bortezomib completed questionnaires about their preference for route of drug delivery; 68 % preferred SC, whilst 25 % favored IV. However, as with many other studies, this was not a randomized controlled trial (RCT). Results from non-randomized studies may affect outcomes due to the potential bias inherent with allocation to intervention groups [25] .
A better understanding of patient preference is fundamental in assisting medical decision making, particularly in patients with chronic health conditions who may be receiving treatment for long periods of time. In this systematic literature review, we considered patient preferences for IV or SC drug administration that had been examined in RCTs and/or crossover designs.
Methods

Search Strategy
A systematic, electronic search of AMED, CINAHL, MEDLINE, PsycINFO, PUBMED, SCOPUS, and Science Direct was performed for articles published up until February 2014. A combined search was used including the terms 'preference', 'intravenous vs. subcutaneous' OR 'intravenous versus subcutaneous' in the various databases.
No restrictions regarding the time period or the type of study were applied during the initial search. A hand search was conducted on the relevant papers retrieved, to examine additional related studies.
Selection Criteria
All duplicates were excluded from the initial computerized search. Only publications of studies that met the following criteria were included: (1) comparison of SC with IV drug administration, (2) investigation of patients' preferences for SC and IV drug administration regardless of measures used, (3) RCTs and/or crossover study designs in which patients had real experience of both methods of administration, (4) original full reports (i.e. conference abstracts or posters, reviews, meta-analyses, and commentaries were excluded), and (5) adults over 18 years.
In the first selection stage, titles, abstracts, and information on the studies were screened to assess whether they were original full reports. In the second stage, abstracts and/or full copies of the articles were reviewed for final selection. Both stages were carried out by two reviewers (KS and HH), and were followed by a hand search.
Data Extraction and Methodological Quality Assessment
Data were extracted from relevant papers using a standardized data extraction form, comprising specific details about the study aims, trial population, intervention, study measures, and outcomes of significance, including the main reasons for preferred patient preference. The methodological quality of each article was assessed using the Cochrane Collaboration's tool for assessing risk of bias, which rates the quality of RCTs [26] . The original version of the tool consists of seven items that are used to assess the risk of bias in the RCTs. However, for this systematic review, the item 'blinding of participants and personnel' was removed, as it is not possible to mask treatment allocation. This resulted in a six-item scoring system using random sequence generation, allocation concealment, blinding of outcome assessment, incomplete outcome data, selective reporting, and other bias. A judgment of risk of bias was assigned to each scoring item (1 = low bias, 0 = high bias or unclear bias), and a total risk of bias score was calculated. Each trial was then assigned a quality rating based on the number of low-risk judgements, ranging from good quality (total score 5-6), to fair quality (3) (4) and to poor quality (0-2). Two reviewers (KS and HH) independently assessed the methodological quality of the included studies. Any differences in rating and/or discrepancies were resolved following discussion.
Results
Search Results
The search produced 151 hits ( Fig. 1 ) from 1974 to February 2014. Duplicates were excluded, leaving 115 potentially relevant studies. The titles, abstracts, and information of these citations were screened for relevance to the review topic, leaving 34 studies to be assessed further. The abstracts and/or full texts of the 34 studies were retrieved, evaluated in detail, and filtered according to the eligibility criteria. After this stage, five studies were left for inclusion in the review [27] [28] [29] [30] [31] . A hand search of the references of relevant citations resulted in an additional study being included in the final review [32] . In total, six studies met the selection criteria; details are summarized in Table 1 .
Four of the RCTs used a crossover design. A total of 410 participants were evaluated across the six studies. The sample sizes ranged from 9 to 248 participants at baseline. The age range of participants (taken from five studies that adequately reported the age range) was 18-85 years. The samples across the six studies predominantly focused on females (83 % female, 17 % male). The study populations were diverse. Studies included participants with cancer, Crohn's disease (CD), primary antibody deficiencies, multifocal motor neuropathy (MMN), primary invasive breast adenocarcinoma, deep vein thrombosis (DVT), and patients scheduled for elective abdominal or extremity surgery.
Study Quality
Three of the studies were of good methodological design with low risk of bias (see Table 1 ). The remaining three studies were of fair methodological quality. In the studies of a fair methodological quality, possible areas of bias were reported in 'random sequence generation' and 'allocation concealment'. In general, the studies seemed sound; however, the possibility of bias was raised due to underreporting, particularly in earlier publications. All studies showed a low risk of bias on the 'incomplete outcome data'.
Patient Preferences
The majority (four of six) of the studies concluded that patients had demonstrated a preference for SC drug administration [27] [28] [29] [30] ; proportions ranged from 44 to 91 %. Only one study reported that patients preferred IV drug delivery [32] , and another found no difference in patient preference for either method [31] .
Assche et al. [28] investigated elective switching between anti-tumor necrosis factor (TNF) agents in patients with CD. The 73 patients either continued receiving IV infliximab or switched to SC adalimumab administered every other week. Patient preference was investigated in the adalimumab arm with a study-specific questionnaire. SC adalimumab was preferred by patients at the majority of time points (six of seven) throughout the trial, but reasons for preference were not reported.
The study by Harbo et al. [29] was conducted in patients with MMN. Patients were randomized to receive either SC or IV immunoglobulin of equal doses. The first therapy was given for a period of 18-56 days. Patients then crossed over to receive the alternative treatment. IV treatment was given in the hospital. During a hospital stay, a nurse taught patients how to self-administer SC immunoglobulin, enabling treatment to be administered at home. Patients gave a detailed description of their preference (method unknown). A total of 44 % (four of nine) of patients had a predilection towards SC immunoglobulin, 22 % (two of nine) favored IV administration, and 33 % (three of nine) gave no preference. Reasons given by patients for SC immunoglobulin preference were that treatment could be given at home and it allowed them to avoid difficulties with IV access. However, patients reported that the increased number in treatment days was a disadvantage for SC immunoglobulin.
Pivot et al. [30] investigated the preferences of women with human epidermal growth factor receptor (HER)-2-positive primary invasive adenocarcinoma of the breast for Another study focused on patients with DVT [27] . Patients were randomized to receive SC calcium heparin or IV sodium heparin. Patients then crossed over to receive the alternative treatment. At the end of the study, patients were questioned on their overall partiality for form of treatment (method unknown). A total of 79 % (15/19) of patients favored the SC route, 11 % (2/19) chose the IV route, and 11 % (2/19) gave no preference. Patients reported significantly less discomfort felt at the SC injection site (p \ 0.001). Patients also perceived that their mobility was better during the last days of treatment when they were receiving SC heparin (p \ 0.005). In contrast, the study by Chapel et al. [32] in patients with primary antibody deficiencies found that patients preferred the IV method of drug administration. Patients received either SC or IV immunoglobulin therapy for 1 year and then received the alternative treatment for an additional year. At the end of the study, patients were asked which method they preferred (methods not reported). Results showed that 62 % (16/26) of patients favored IV application compared with the 38 % (10/26) of patients who preferred the SC route. Four patients had no preference. Reasons for preference were not reported.
Urquhart et al. [31] assessed patient-controlled analgesia (PCA) in patients undergoing elective abdominal or extremity surgery. Patients were randomized to receive either SC or IV PCA. When patients reported pain, hydromorphone was administered until they no longer experienced any discomfort. A PCA infuser was then attached to the patient, allowing patients to self-administer hydromorphone either IV or SC for the duration of their stay in the hospital. After completion of PCA therapy, patients were asked about their overall satisfaction with the technique via a study-specific questionnaire. Of the patients in the SC group, 80 % (12/15) rated their pain control as excellent, as did 67 % (10/15) of patients in the IV group. However, patients' ratings of overall satisfaction in their analgesic therapy did not differ between both treatment groups.
Quality of Life
Two studies also reported on patients' quality of life (QoL) in addition to preference. In the study by Harbo et al. [29] , patients completed the generic SF-36 questionnaire [33] . The hypothesis was that QoL would improve in patients with MMN following SC delivery of immunoglobulin, as this could be given at home. Although SC administration was the preferred route of most patients in the study, no significant differences in the QoL scores were found. Assche et al. [28] used the disease-specific inflammatory bowel disease (IBD) questionnaire to measure QoL [34] . This enquired about general preference, the benefit from therapy, mode of administration, impact on activities of daily life, burden of adverse events, and financial implications. All factors except for the financial implications contributed to patient preference for SC over IV administration. A larger number of patients reported no preference for either SC or IV in respect to the financial impact of the treatment.
Efficacy and Safety
The focus of this review is on patient preferences, but the primary outcome in four of six studies [27, 29, 31, 32] was testing the non-inferiority of SC to IV drug delivery and all demonstrated comparable efficacy and safety profiles for the two methods of drug administration. Only two studies had patient preference as the primary outcome in the trial [28, 30] . In the Pivot et al. [30] study, the primary outcome of an overwhelming preference for SC trastuzumab attributed additional support for the use of the formulation to the favorable pharmacokinetic profile and non-inferior efficacy outcomes. In contrast, the Assche et al. [28] study had rather mixed results. They reported treatment termination because of poor tolerance of 10/36 patients receiving SC adalimumab compared with only one patient in the IV drug administration arm. A loss of efficacy was shown in 4/36 patients receiving SC adalimumab; despite this, patients still reported a preference for SC administration.
Discussion
The present review evaluated patients' preferences within RCTs for either SC or IV drug administration. An extensive literature search revealed six RCTs [27] [28] [29] [30] [31] [32] . Despite the heterogeneity of the studies, overall findings demonstrate a clear patient preference, ranging from 44 % [29] to 91 % [30] , for the SC route. Factors associated with SC preference were that patients were able to have the treatment at home [29] , and that it saved time (e.g. travel time to the hospital) [29] , avoided problems with IV administration or venous access [29, 30] , and reduced discomfort [27] .
The studies included in this review not only showed diversity regarding patient population and the drugs investigated, but also in the period of time that the drugs were administrated. Treatment time ranged from 2 days in a PCA trial [31] to 2 years in a trial examining immunoglobulin-replacement therapy in patients with primary antibody deficiencies [32] . This is important to take into account, as patient preference for administration route may differ according to the length of time patients spend receiving the drug. For example, patients who require longterm drug treatment may experience damage to their veins, which no longer enables them to tolerate IV delivery. These patients may welcome SC administration, whereas those who are given drugs for a shorter duration or in a one-off treatment may not be affected and therefore show little or no preference for mode of drug delivery. Our review suggests that longer treatment regimens were associated with preference for SC administration [28] [29] [30] .
The methods employed to measure patient preference outcomes varied between studies. Three studies lacked a description of study measures [27, 29, 32] , making interpretation of the results difficult. The three remaining studies used study-specific instruments (either questionnaires or field-tested interviews [28, 30, 31] ). The need to develop study-specific measures for contemporaneous preference studies with patients actually receiving treatment can be time consuming and requires a high degree of expertise and often additional funding. This is probably why they are rarely performed, although a large amount of research literature exists primarily for health economic assessments using stated-preference techniques such as discrete-choice experiments, standard gamble, and willingness to pay [35] [36] [37] .
A strength of the current review is that only RCTs and/ or crossover designs were included. This is very important, as in cases where patients are being treated for chronic conditions, other study designs may attract those who are having trouble with or dislike their current treatment method, which would result in bias. Although a few other good-quality studies examine patient preferences [18] [19] [20] [21] [22] [23] [24] , none are RCTs. For example, one study measured preferences of IBD patients for two anti-TNF agents in terms of their mode of administration by using hypothetical scenarios [18] . However, until patients actually have the drugs administered and experience the different modes of delivery, the route they favor may differ.
Our review has several limitations. One of these is the appraisal system we used [26] . This particular method focused on whether or not the study had been properly set up as an RCT to eliminate bias, rather than as an in-depth appraisal that may have been achieved by using another process. In addition, as blinding for treatment allocation was not possible in most studies (only one study was single-blinded [29] ), part of this tool could not be used.
As far as we are aware, this is the first review focusing on patients' preferences for either IV or SC administration. One other review compared different aspects of SC and IV routes (including health-related QoL, treatment satisfaction, and convenience) but only included studies in patients with primary or secondary antibody deficiencies [38] .
A partiality by patients for administration route is an important issue that needs more consideration, especially as time is a very precious commodity for patients with lifethreatening and/or chronic disease. The extra survival time achieved through efficacious drugs needs to be balanced against the effort and burden required to have the treatment administered. Both the lack of literature and the fact that only one study assessed patient preference as the primary outcome measure [30] demonstrate how neglected this area is. This evidence suggests that patients are not given the opportunity to decide which medical treatment is most beneficial to them. Patient preference is a significant factor in treatment-related decision making and could possibly affect patient QoL and treatment compliance. Having a choice of mode of drug delivery also allows clinicians to adopt a more patient-centric treatment approach based on a patient's specific needs.
Addressing patient preferences in future research is vital in regards to medical decision making. Future studies ought to be RCTs or crossover designs in order to retrieve the most objective results and to reduce risk of bias, incorporating health-related QoL. Relatives might also highlight other putative benefits associated with route of administration. There is also scope for some standardisation in the methodology employed to measure preferences, as this would increase the validity within the research. We recognize that it may be difficult to produce a generic instrument that could be used across all studies but we suggest that study-specific research measures, like short questionnaires or structured interviews, are piloted in a group of patients to address concept validity. If the safety and efficacy of IV and SC drug administration is proven to be non-inferior to one another, patients should have a choice in what route they receive, based on their individual choice. This is particularly the case for individuals who undergo long-term treatment for chronic diseases.
